A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Temsirolimus (Primary) ; Carboplatin; Docetaxel; Paclitaxel
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms GOG-0268
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 23 Nov 2015 Status changed from active, no longer recruiting to completed as reported by clinicalTrials.gov record.
- 25 Nov 2013 Planned number of patients changed from 45 to 90 as reported by ClinicalTrials.gov record.